Trade Precigen, Inc. - PGEN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.06 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.96 |
| Open | 0.95 |
| 1-Year Change | -39.87% |
| Day's Range | 0.92 - 0.96 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 10, 2024 | 0.96 | 0.00 | 0.00% | 0.96 | 0.96 | 0.92 |
| Sep 9, 2024 | 0.94 | 0.01 | 1.08% | 0.93 | 0.97 | 0.93 |
| Sep 6, 2024 | 0.92 | -0.01 | -1.08% | 0.93 | 0.96 | 0.90 |
| Sep 5, 2024 | 0.94 | -0.04 | -4.08% | 0.98 | 0.98 | 0.93 |
| Sep 4, 2024 | 0.94 | -0.09 | -8.74% | 1.03 | 1.03 | 0.93 |
| Sep 3, 2024 | 1.03 | -0.03 | -2.83% | 1.06 | 1.08 | 1.03 |
| Aug 30, 2024 | 1.07 | -0.03 | -2.73% | 1.10 | 1.11 | 1.05 |
| Aug 29, 2024 | 1.09 | -0.01 | -0.91% | 1.10 | 1.15 | 1.09 |
| Aug 28, 2024 | 1.11 | 0.00 | 0.00% | 1.11 | 1.13 | 1.09 |
| Aug 27, 2024 | 1.12 | 0.01 | 0.90% | 1.11 | 1.13 | 1.09 |
| Aug 26, 2024 | 1.13 | -0.01 | -0.88% | 1.14 | 1.16 | 1.12 |
| Aug 23, 2024 | 1.13 | 0.02 | 1.80% | 1.11 | 1.16 | 1.10 |
| Aug 22, 2024 | 1.10 | -0.06 | -5.17% | 1.16 | 1.18 | 1.10 |
| Aug 21, 2024 | 1.17 | 0.07 | 6.36% | 1.10 | 1.17 | 1.10 |
| Aug 20, 2024 | 1.11 | -0.01 | -0.89% | 1.12 | 1.15 | 1.10 |
| Aug 19, 2024 | 1.12 | 0.05 | 4.67% | 1.07 | 1.14 | 1.07 |
| Aug 16, 2024 | 1.07 | 0.02 | 1.90% | 1.05 | 1.08 | 1.04 |
| Aug 15, 2024 | 1.05 | -0.04 | -3.67% | 1.09 | 1.17 | 1.05 |
| Aug 14, 2024 | 1.10 | -0.09 | -7.56% | 1.19 | 1.23 | 1.09 |
| Aug 13, 2024 | 1.06 | 0.02 | 1.92% | 1.04 | 1.06 | 1.03 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Precigen, Inc. Company profile
About Precigen Inc
Precigen, Inc. (Precigen) is a synthetic biology company that focuses on its discovery and clinical-stage activities to advance gene and cellular therapies to target immuno-oncology, autoimmune disorders, and infectious diseases. Its therapeutic platforms, including UltraCAR-T, AdenoVerse immunotherapy, and ActoBiotics, are designed to precisely control the level and physiological location of gene expression and modify biological molecules to control the function and output of living cells to treat underlying disease conditions. The Company’s lead clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. The Company also completed a Phase I study of INXN-4001, a non-viral triple-effector plasmid DNA, which is built on its UltraVector platform. It also has a robust pipeline of preclinical programs.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Precigen Inc revenues increased 1% to $103.9M. Net loss before extraordinary items decreased 7% to $96.8M. Revenues reflect Tranns Ova segment increase of 26% to $89.6M. Lower net loss reflects General and administrative - Balancing decrease of 15% to $63.2M (expense), Stock-based Compensation in SGA decrease of 38% to $11M (expense).
Equity composition
Common Stock, no Par, 08/13, 185M auth., 95,210,329 issd., Insider Owns approx.89.50%.
| Industry: | Pharmaceuticals (NEC) |
20374 Seneca Meadows Parkway
GERMANTOWN
MARYLAND 20876
US
News
ECB Preview: cuts expected but the pace is uncertain
Markets expect the ECB to cut rates again in September, but how many more?
12:34, 11 September 2024
Market analysis: US CPI and PPI
Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.
07:56, 10 September 2024
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024
Jackson Hole Preview: All eyes on Powell and Gold
The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.
15:24, 19 August 2024
All eyes on inflation: US and UK CPI take centre stage
Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.
14:41, 13 August 2024
European stocks face resistance in their attempt to recover
European stocks struggle to recover as the tech sector faces continued downside pressure in Asia.
13:56, 9 August 2024
Global selloff continues on US economy fears
Thursday’s rise in jobless claims led to a market meltdown in the US stock market as investors became concerned that the Federal Reserve made the wrong decision by keeping rates unchanged on Wednesday.
14:40, 5 August 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com